Evidence map›Paper›PMID 34439373›Full record

ArticleCancers2021

Low Doses of Silver Nanoparticles Selectively Induce Lipid Peroxidation and Proteotoxic Stress in Mesenchymal Subtypes of Triple-Negative Breast Cancer.

Christina M Snyder, Monica M Rohde, Cale D Fahrenholtz, Jessica Swanner, John Sloop, George L Donati, Cristina M Furdui, Ravi Singh

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christina M SnyderDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.ORCID 0000-0001-8569-2939
Monica M RohdeDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
Cale D FahrenholtzDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
Jessica SwannerDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
John SloopDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA.
George L DonatiDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA.
Cristina M FurduiDepartment of Internal Medicine, Section of Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Ravi SinghDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.ORCID 0000-0003-0750-1804
Wake Forest University · USAtrium Health Wake Forest Baptist · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
New Oxidation-Sensing Probes to Evaluate Mitochondrial Dysfunction in Lung InjuryR33ES025645 · NIEHS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FURDUI, CRISTINA MARIA, KING, S BRUCE · 2017 to 2019
$1.5M
Redox Biology and Medicine Training ProgramT32GM127261 · NIGMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FURDUI, CRISTINA MARIA, POOLE, LESLIE B · 2018 to 2022
$975k
National Science Foundation, USA CHE-1531698NCATS NIH HHS UL1 TR001420NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA207222NCI NIH HHS R01CA207222NIEHS NIH HHS R33 ES025645NIEHS NIH HHS R33ES025645NIGMS NIH HHS T32 GM127261NIGMS NIH HHS T32GM127261
6 · The paper itself

Abstract

Molecular profiling of tumors shows that triple-negative breast cancer (TNBC) can be stratified into mesenchymal (claudin-low breast cancer; CLBC) and epithelial subtypes (basal-like breast cancer; BLBC). Subtypes differ in underlying genetics and in response to therapeutics. Several reports indicate that therapeutic strategies that induce lipid peroxidation or proteotoxicity may be particularly effective for various cancers with a mesenchymal phenotype such as CLBC, for which no specific treatment regimens exist and outcomes are poor. We hypothesized that silver nanoparticles (AgNPs) can induce proteotoxic stress and cause lipid peroxidation to a greater extent in CLBC than in BLBC. We found that AgNPs were lethal to CLBCs at doses that had little effect on BLBCs and were non-toxic to normal breast epithelial cells. Analysis of mRNA profiles indicated that sensitivity to AgNPs correlated with expression of multiple CLBC-associated genes. There was no correlation between sensitivity to AgNPs and sensitivity to silver cations, uptake of AgNPs, or proliferation rate, indicating that there are other molecular factors driving sensitivity to AgNPs. Mechanistically, we found that the differences in sensitivity of CLBC and BLBC cells to AgNPs were driven by peroxidation of lipids, protein oxidation and aggregation, and subsequent proteotoxic stress and apoptotic signaling, which were induced in AgNP-treated CLBC cells, but not in BLBC cells. This study shows AgNPs are a specific treatment for CLBC and indicates that stratification of TNBC subtypes may lead to improved outcomes for other therapeutics with similar mechanisms of action.

Indexed as

claudin lowEMTlipid peroxidationnanomedicineprecision medicineproteotoxic stresssilver nanoparticletriple-negative breast cancer

Identifiers

PMID34439373
PMCPMC8393662
OpenAlexW3194421764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.